

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/66, C07F 9/09, 9/40	A1	(11) International Publication Number: WO 98/40080 ✓ (43) International Publication Date: 17 September 1998 (17.09.98)
--	----	---

(21) International Application Number: ✓ PCT/US98/04834

(22) International Filing Date: 11 March 1998 (11.03.98) ✓

(30) Priority Data:
08/814,386 ✓ 11 March 1997 (11.03.97) ✓ US(71) Applicant: BEACON LABORATORIES, L.L.C. [US/US];
Wayne Plaza 1, Suite 303, 145 Route 46, Wayne, NJ 07470
(US). → 18306(72) Inventors: NUDELMAN, Abraham, Miller 15 Street, 76284
✓ Rehovot (IL). REPHABLI, Ada, Hanuriot 10, 46726
Herzeliya Pitoach (IL) ✓(74) Agents: TSEVDOS, Estelle, J. et al.; Kenyon & Kenyon, One
Broadway, New York, NY 10004 (US).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent
(GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: OXYALKYLENE PHOSPHATE COMPOUNDS AND USES THEREOF

(57) Abstract

This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and in particular, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, treating, preventing or ameliorating protozoan infection, or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use oxyalkylene phosphate compounds.